Amyotrophic Lateral Sclerosis – TDP-43 Seeding Mouse Models
Recapitulate the key structural features and spreading of TDP-43 proteinopathy found in the brain of ALS patients using TDP-43 Seeding Mouse Models
TDP-43 Seeding Mouse Models Key Characteristics
TDP-43 seeding mouse models are established by injecting brain extracts from patients affected by TDP-43 proteinopathy. TAR DNA binding protein (TDP-43) encoded by TARDBP gene, is a major protein involved in the pathogenesis of Amyothropic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Therefore, injection of brain extracts from these diseases in the brain of mice closely mimics the structural features of TDP-43 aggregates found in patients, and allows studying the pathologic spreading of TDP-43 in response to novel compounds as a therapeutic readout.
As part of our specialised preclinical research services, InnoSer offers research services including efficacy studies in TDP-43 seeding mouse models, using either recombinant and/or patient-derived seeds. Accordingly, brain extracts from both ALS and FTD patients can be used, mimicking the unique disease pathophysiology, with the choice of the brain source extracts ultimately depending on your target disease of interest.
✓ Recombinant and patient-derived TDP-43 brain extract seeds are available.
✓ TDP-43 aggregates can be injected in both wild-type (WT) or transgenic mice.
Take advantage of InnoSer’s preclinical contract research expertise in modelling TDP-43 pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience working with seeding-based ALS, but also other neurodegenerative disease models. We are happy to help guide your decision on study design fit for your current research goals.
As part of InnoSer’s neurology ALS mouse model portfolio, we also offer efficacy studies in mouse models with TDP-43 pathology, including transgenic TDP-43 mouse models, as well as a SOD1-G93A transgenic ALS mouse model. However, as each model is unique, modelling distinct pathophysiological aspects of ALS, we recommend you discuss the most appropriate model with our neurology study directors.
Your ALS Research Starts Here.
View study timelines, recommended readouts, and example data featuring behavioral across different ALS mouse models.
TDP-43 Seeding Mouse Models Readouts
Biological Readouts
Test the efficacy of your treatments with the following biological readouts:
- Immunohistochemistry (TDP-43 accumulation, neuroinflammation)
- Immunofluorescence and FISH
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Discover Other Relevant Neurological Disease Models
Discover InnoSer’s Latest Research
MDX Mouse Model Validation Data
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...
InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading...
Introduction to InnoSer’s Preclinical Epilepsy Research CRO Platform
Preclinical epilepsy-related research with InnoSer Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
Phenotyping of a C3-PMP22 mouse model of CMT1A
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Ready to work with a CRO that’s as committed as you are?
Join us in delivering impactful studies that bring therapies to patients sooner.
info@innoserlaboratories.com